The low expression of ALIN, ARHGAP11A, ASPM, ATP6V0B, BUB1, CENPF, DLGAP5, CEP55, MKI67, TOP2A, TTK was more favorable to the long-term survival of BC patients, while the high expression of CAB39L, HBA2, STAT5, KIT, MAMDC2, MLPH, TGFBR2, SLC16A6, FOS, OLFML2B was more associated with the long-term survival of BC patients. Here, FOS is linked to breast cancer.